Other Targeted Therapies
- Avastin (bevacizumab) – approved for stage 4 NSCLC patients in combination with platinum doublet chemotherapy.
-
Bizengri (zenocutuzumab-zbco) – approved for stage 4 NSCLC patients with an NRG1 gene fusion mutation who have progressed on or after prior systemic therapy.
- Cyramza (ramacirumab) – approved for stage 4 NSCLC patients in combination with chemotherapy who have progressed on platinum doublet chemotherapy. Cyramza is also approved in combination with Tarceva for stage 4 NSCLC patients with either an EGFR exon 19 deletion or exon 21 substitution changes as detected by a biomarker test.
- Enhertu (fam-trastuzumab deruxtecan-nxki) – approved for stage 4 NSCLC with an activating mutation in HER2 as detected by a biomarker test for patients who have already received one line of treatment.
- Mvasi (bevacizumab-awwb) – approved for stage 4 NSCLC patients in combination with platinum doublet chemotherapy.